On June 14, Eurosurveillance published new information on the characteristics of the German outbreak strain of E.coli and how these microbiological findings have been shared in real time by public health microbiology experts to disseminate best laboratory practice for case detection and public health investigations across Europe and beyond.
In the context of the ongoing outbreak of Shiga toxin-producing E. coli (STEC) that affects by now citizens from 13 EU member states, it is crucial not only to align the efforts regarding investigation and control of the outbreak but also to share knowledge among practitioners across Europe on the patho-physiological and clinical characteristics of infection caused by this unusual epidemic strain, and review patient management options.
Today, the German authorities published a press release on the current Shiga toxin-producing E.coli outbreak. In their joint statement they recommended in particular to abstain from eating raw sprouts.
ECDC Director Marc Sprenger at the European Parliament Committee on the Environment, Public Health and Food Safety (ENVI) stressed the importance of the EU’s continuous commitment in the fight against hepatitis B and hepatitis C.
In September 2010, two cases of autochthonous dengue fever were diagnosed in metropolitan France for the first time. The cases occurred in Nice, southeast France, where the vector Aedes albopictus is established.
Aedes aegypti is a highly specialized mosquito species feeding predominantly on humans and breeding in artificial water holding containers in urban areas, and currently restricted to subtropical and tropical areas. Williams et al. focus on the reasons why Ae. aegypti once occurred in locations where the mosquito does not occur anymore in Australia, the more temperate drier parts of the country.
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.